222 related articles for article (PubMed ID: 35042012)
1. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis.
Gabanti E; Borsani O; Colombo AA; Zavaglio F; Binaschi L; Caldera D; Sciarra R; Cassinelli G; Alessandrino EP; Bernasconi P; Ferretti VV; Lilleri D; Baldanti F
Transplant Cell Ther; 2022 Apr; 28(4):211.e1-211.e9. PubMed ID: 35042012
[TBL] [Abstract][Full Text] [Related]
2. Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients.
Zavaglio F; Vitello D; Bergami F; Arena F; Borsani O; Colombo AA; Caldera D; Lilleri D; Cassaniti I; Bernasconi P; Baldanti F
J Clin Virol; 2023 Aug; 165():105519. PubMed ID: 37321150
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis.
Lauruschkat CD; Muchsin I; Rein A; Erhard F; Grathwohl D; Dölken L; Köchel C; Falk CS; Einsele H; Wurster S; Grigoleit GU; Kraus S
Front Immunol; 2023; 14():1148841. PubMed ID: 37234158
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
5. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
[TBL] [Abstract][Full Text] [Related]
6. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
[TBL] [Abstract][Full Text] [Related]
7. Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation.
Lauruschkat CD; Muchsin I; Rein AF; Erhard F; Grathwohl D; Dölken L; Köchel C; Nehmer A; Falk CS; Grigoleit GU; Einsele H; Wurster S; Kraus S
Blood Adv; 2024 Jun; 8(11):2967-2979. PubMed ID: 38315873
[TBL] [Abstract][Full Text] [Related]
8. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
Chen TT; David AP; Barthelmess EK; MacBrayne CE
Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Russo D; Schmitt M; Pilorge S; Stelljes M; Kawakita T; Teal VL; Haber B; Bopp C; Dadwal SS; Badshah C
Lancet Haematol; 2024 Feb; 11(2):e127-e135. PubMed ID: 38142695
[TBL] [Abstract][Full Text] [Related]
10. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38838781
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
[TBL] [Abstract][Full Text] [Related]
12. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
13. Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir.
Orofino G; Xue E; Doglio M; Noviello M; Tassi E; Cristante M; Acerbis A; Clerici D; Farina F; Campodonico E; Bruno A; Piemontese S; Mastaglio S; Diral E; Milani R; Ruggeri A; Corti C; Vago L; Bonini C; Peccatori J; Ciceri F; Lupo Stanghellini MT; Greco R
Bone Marrow Transplant; 2023 Oct; 58(10):1104-1111. PubMed ID: 37468541
[TBL] [Abstract][Full Text] [Related]
14. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation.
Zamora D; Duke ER; Xie H; Edmison BC; Akoto B; Kiener R; Stevens-Ayers T; Wagner R; Mielcarek M; Leisenring WM; Jerome KR; Schiffer JT; Finak G; De Rosa SC; Boeckh M
Blood; 2021 Jul; 138(1):34-43. PubMed ID: 33657225
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
[TBL] [Abstract][Full Text] [Related]
17. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
[TBL] [Abstract][Full Text] [Related]
18. Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
Studer U; Khanna N; Leuzinger K; Hirsch HH; Heim D; Lengerke C; Tsakiris DA; Halter J; Gerull S; Passweg J; Medinger M; Gwerder M
Anticancer Res; 2020 Oct; 40(10):5909-5917. PubMed ID: 32988922
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
Piret J; Goyette N; Boivin G
Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
[TBL] [Abstract][Full Text] [Related]
20. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
